~30 min (no DAC / Mod GRF 1-29) / ~8 days (with DAC)
26 minutes (IV), ~38 minutes (SC)
Admin routes
subcutaneous
subcutaneous
Research areas
Growth hormone optimizationBody compositionRecovery and repairAnti-agingIGF-1 elevationSleep quality
HIV-associated lipodystrophyVisceral adipose tissue reductionHepatic steatosis (NAFLD/NASH)Body compositionCognitive function
Typical dosing
100–300 mcg · 1-3x daily (no DAC) / 2x weekly (DAC) · 8-12 weeks
1000–2000 mcg · 1x daily · 26 weeks minimum (per Egrifta label); ongoing if responding
FDA status
Not FDA-approved. Not on the 503A bulks list and in none of FDA's interim Category 1, 2, or 3 lists — there is no lawful 503A or 503B compounding route.
FDA-approved (Egrifta/Egrifta SV) for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy
WADA status
Prohibited (S2 — peptide hormones, growth factors, and related substances)
Prohibited at all times (S2 - Peptide Hormones, Growth Factors)
